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Abstract
BACKGROUND
Circulating microRNAs (miRNAs) are potential biomarkers for many diseases.
However, they can originate from non-disease specific sources, such as blood
cells, and compromise the investigations for miRNA biomarkers. While small
extracellular vesicles (sEVs) have been suggested to provide a purer source of
circulating miRNAs for biomarkers discovery, the most suitable blood sample for
sEV miRNA biomarker studies has not been defined.
AIM
To compare the miRNA profiles between matched serum and plasma sEV
preparations to determine their suitability for biomarker studies.
METHODS
Matched serum and plasma samples were obtained from 10 healthy controls and
10 patients with esophageal adenocarcinoma. sEV isolates were prepared from
serum and plasma using ExoQuickTM and quantified using NanoSight. RNA was
extracted from sEV preparations with the miRNeasy Serum/Plasma kit and
profiled using the Taqman Openarray qPCR. The overall miRNA content and the
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expression of specific miRNAs of reported vesicular and non-vesicular origins
were compared between serum and plasma sEV preparations. The diagnostic
performance of a previously identified multi-miRNA biomarker panel for
esophageal adenocarcinoma was also compared.
RESULTS
The overall miRNA content was higher in plasma sEV preparations (480
miRNAs) and contained 97.5% of the miRNAs found in the serum sEV
preparations (412 miRNAs).The expression of commonly expressed miRNAs was
highly correlated (Spearman’s R = 0.87, P <  0.0001) between the plasma and
serum sEV preparations, but was consistently higher in the plasma sEV
preparations. Specific blood-cell miRNAs (hsa-miR-223-3p, hsa-miR-451a, miR-
19b-3p, hsa-miR-17-5p, hsa-miR-30b-5p, hsa-miR-106a-5p, hsa-miR-150-5p and
hsa-miR-92a-3p) were expressed at 2.7 to 9.6 fold higher levels in the plasma sEV
preparations compared to serum sEV preparations (P < 0.05). In plasma sEV
preparations, the percentage of protein-associated miRNAs expressed at
relatively higher levels (Ct 20-25) was greater than serum sEV preparations (50%
vs 31%). While the percentage of vesicle-associated miRNAs expressed at
relatively higher levels was greater in the serum sEV preparations than plasma
sEV preparations (70% vs 44%). A 5-miRNA biomarker panel produced a higher
cross validated accuracy for discriminating patients with esophageal
adenocarcinoma from healthy controls using serum sEV preparations compared
with plasma sEV preparations (AUROC 0.80 vs 0.54, P < 0.05).
CONCLUSION
Although plasma sEV preparations contained more miRNAs than serum sEV
preparations, they also contained more miRNAs from non-vesicle origins. Serum
appears to be more suitable than plasma for sEV miRNAs biomarkers studies.
Key words: Biomarkers; Exosomes; Extracellular vesicles; Circulating microRNA;
MicroRNAs; Plasma; Serum; Blood cells; Real-time polymerase chain reaction;
Adenocarcinoma of esophagus
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: Current evidence suggests that circulating small extracellular vesicles (sEVs)
function as delivery cargo shuttles for various molecules. MicroRNAs are small non-
coding RNAs with important roles in the regulation of gene expression, are often
dysregulated in diseases, and are relatively stable in the circulation. MicroRNAs
circulating in sEVs are consequently considered as highly suitable candidates for use as
non-invasive biomarkers. Extracellular vesicle preparations derived from serum and
plasma are recognised to be enriched in sEVs, but not purely comprised of them. Most
circulating sEV microRNA biomarker studies have used plasma, but here we show that
sEVs isolated from serum are less contaminated with blood cell and protein-associated
microRNAs.
Citation: Chiam K, Mayne GC, Wang T, Watson DI, Irvine TS, Bright T, Smith LT, Ball IA,
Bowen JM, Keefe DM, Thompson SK, Hussey DJ. Serum outperforms plasma in small
extracellular vesicle microRNA biomarker studies of adenocarcinoma of the esophagus.




MicroRNAs (miRNAs) are small non-coding RNA molecules (21-23 nucleotides) that
can  regulate  gene  expression  via  various  mechanisms  including  repression  of
messenger  RNA translation.  miRNAs are  important  regulators  because  a  single
miRNA  can  target  multiple  genes.  Furthermore,  specific  miRNA  expression
signatures have been shown to be tissue-specific[1], and disease-specific[2-4]. miRNAs
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are found in a range of body fluids such as serum, plasma, whole blood, urine and
saliva.  These  circulating  miRNAs are  highly  stable  in  different  conditions  (e.g.,
temperature, pH and storage period) and can be easily measured. For these reasons,
circulating  miRNAs  have  garnered  significant  research  interest  as  potential
biomarkers for diagnostic, prognostic and treatment prediction purposes.
However,  there are many challenges in the process of  biomarker discovery to
clinical practice for circulating miRNAs. Various factors can influence the quality and
outcome  of  biomarker  studies,  which  include  the  choice  of  sample,  processing
conditions, biomarker detection and analysis methods[5,6].  There is also increasing
awareness  about  the  multiple  origins  of  specific  circulating  miRNAs  and  the
implications this has on how we should evaluate and interpret miRNAs biomarkers
studies[7-10].  A  study  by  Pritchard  et  al[8]  highlighted  that  a  large  proportion  of
circulating miRNA cancer biomarkers identified in the literature overlapped with
those that have been reported to be highly expressed in blood cells. This has raised
concerns on factors such as hemolysis and whether different types of blood samples
used in miRNA studies may vary in their content of miRNAs originating from blood-
cells.
Small extracellular microvesicles (sEVs), are considered to be a more stable and
disease-specific  source  of  circulating miRNAs for  biomarker  development[11].  In
cancers, circulating miRNAs encapsulated in sEVs have been shown to have critical
functional roles such as regulating disease progression, metastasis and sensitivity to
specific  drugs[12].  Circulating  miRNAs  can  also  be  found  complexed  with  the
Argonaute2 (Ago2) protein, which functions to protect the miRNAs against RNases
and enhance their stability in the circulation[13,14]. Although these protein-associated
circulating miRNAs have been found to be present in larger quantities than sEV
miRNAs,  their  functional  roles  in  disease  pathogenesis  and  potential  utility  as
biomarkers have not been investigated. Thus far, the focus remains on circulating sEV
miRNAs as preferred candidates for biomarkers development and protocol-related
studies[11,15-17].
A crucial step in the development of robust circulating miRNAs biomarkers is to
determine  which  blood  sample  is  optimum for  the  study.  This  is  a  challenging
question  to  address  due  to  the  multiple  origins  of  circulating  miRNAs  and
experimental  factors  that  can  influence  miRNA  levels.  Previous  studies  have
endeavoured to address this  question by comparing circulating miRNA profiles,
mostly  of  cell-free  miRNAs  across  different  blood  samples,  and  have  reported
inconsistent results[10,11,16,18,19]. There are only limited studies that have comprehensively
investigated and reported sEV miRNAs profiles between different blood samples[11,13].
In this study, we compared miRNA profiles between matched serum and plasma sEV
preparations,  collected  from  healthy  controls  and  patients  with  esophageal
adenocarcinoma, for the presence of reported specific vesicular and non-vesicular
miRNAs.  We  also  compared  the  performance  of  a  previously  identified  multi-
biomarker panel (comprising of 5 sEV miRNA ratios)[20], between serum and plasma
sEV preparations, to discriminate patients with esophageal adenocarcinoma from the
healthy individuals.
MATERIALS AND METHODS
Patient recruitment and sample collection
Individuals visiting Flinders Medical Centre (Adelaide, South Australia) and the
Royal Adelaide Hospital (Adelaide, South Australia) for endoscopy procedures and
management of esophageal cancer were recruited for a biomarker research study.
Ethical approval was obtained from the Southern Adelaide Clinical Human Research
Ethics  Committee  and  the  Royal  Adelaide  Hospital  Research  Committee.  All
individuals provided written informed consent for blood and personal data collection
for research purposes. The study was conducted in accordance with the Declaration of
Helsinki’s (2008) statement for the ethical principles for medical research involving
human subjects.
Blood samples from 10 healthy controls (median age 56.5 ± 10) and 10 patients with
locally advanced esophageal adenocarcinoma (median age 59.5 ± 7) were used. The
individuals  were  previously  part  of  a  larger  biomarker  study  for  esophageal
adenocarcinoma[20]. The “healthy controls” all underwent endoscopy with biopsies
and were  not  identified  as  having Barrett’s  esophagus,  gastroesophageal  reflux
disease, or cancer. Only individuals with no endoscopic or histological abnormality
were included in the control group. Matched serum and plasma samples from each
individual was collected at the same time prior to their endoscopy procedure. Blood
was collected from the patients with cancer prior to any treatment. Collection was
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performed with 8 mL Z Serum Separator Clot Activator tubes Vacuette® (cat# 455078)
and 9 mL K3E K3EDTA tubes Vacuette® (cat# 455036) respectively.
Blood processing and extracellular vesicle isolation
All  blood samples  were  left  at  room temperature  for  a  period of  16-24  h  before
processing with a standardised protocol established in our laboratory. Serum was
collected via centrifugation of blood at 650 g for 15 min and stored as 1 mL aliquots at
-80 °C for later use. Plasma was collected via  centrifugation at 650 g  for 15 min to
separate the plasma supernatant from the red blood cells and buffy coat containing
white blood cells. The top clear layer of plasma supernatant was transferred to a fresh
10  mL  tube  (Techno-Plas  Pty  Ltd.,  Australia;  cat#  S9716-V06)  for  a  second
centrifugation at 650 g for 15 min and the supernatant was stored as 1 mL aliquots at -
80 °C for later use.
For extracellular vesicle isolation, aliquots (1 mL) of the matched serum and plasma
from the 10 healthy controls and 10 patients with esophageal adenocarcinoma were
retrieved from -80 °C and quick thawed. The aliquots were centrifuged at 16000 g at 4
°C for  30 min to  exclude large microparticles.  Two hundred and fifty  microliter
supernatants  from each sample  was processed with the  ExoQuickTM  kit  (System
Biosciences,  CA,  United  States;  EXOQ20A-1)  according  to  the  manufacturer’s
protocol.  All  samples  were  incubated  with  ExoQuickTM  at  4  °C  for  16  h.  The
extracellular vesicle pellet isolated from each sample was resuspended with 50 µL
phosphate buffered saline.
Size distribution and quantification of extracellular vesicles
The size and concentration of extracellular vesicles isolated from each sample was
measured using a NanoSight LM10 Nanoparticle Analysis System and Nanoparticle
Tracking  Analysis  Software  (NanoSight  Ltd.,  Malvern,  United  Kingdom).  One
microliter of vesicle suspension was serially diluted in pre-filtered phosphate buffered
saline to a dilution factor of 1:3200 for the NanoSight measurement. This dilution
factor was determined in the laboratory to achieve an average particle concentration
range  of  108-109/mL for  our  samples,  which  is  the  optimal  measurement  range
recommended by the manufacturer’s protocol. The diluted sample was injected into
the NanoSight  instrument  sample  inlet  port  and a  60  s  video were  captured for
measurement.  The  measurements  were  performed in  triplicate  for  each  diluted
sample by re-injecting the same sample into the sample inlet port. Average particle
size and concentration for each sample was evaluated using the batch-processing
settings within the NTA software.
Extracellular vesicle miRNA extraction and profiling
The miRNeasy Serum/Plasma kit (QIAGEN, #217184) was used according to the
manufacturer’s protocol. After the addition of 500 µL QIAzol Lysis reagent to each
vesicle pellet, 5 µL (0.1 picomole) of each of the synthetic RNA molecules ath-miR-
159a and cel-miR-54 were added (Shanghai Genepharma Co. Ltd.). The final RNA
elution from each sample was performed with 24 µL of RNase-free ultrapure water.
The Taqman® OpenArray® Human microRNA panel (Life technologies, #4461104)
was used to profile the expression of 758 miRNAs. The detailed steps for the miRNA
profiling were as previously described[20].  The profiling was performed using the
Biotrove OpenArray NT cycler at the Flinders Genomics Facility (Flinders University,
South Australia). The Realtime PCR Statminer® software (v4.5, Integromics) was used
to assess the miRNA expression as cycle threshold (Ct) value per assay. The relative
miRNA expression was calculated as 2(40-Ct). The data has been submitted to the Gene
Expression Omnibus website (GSE142855).
Statistical analysis
Wilcoxon signed-rank test was used to investigate the pairwise differences between
the matched serum and plasma samples of individual. This included comparisons on
the particle concentrations, number of miRNAs detected and relative expression of
specific miRNA. Correlation was assessed using the Spearman’s rank correlation
coefficient. The diagnostic accuracy of a previously identified 5-miRNA ratio panel[20]
was  determined  using  leave-one-out  cross-validation  and  receiver-operating
characteristics (ROC) curve analysis. Statistical significance was defined by a P value
<  0.05.  Statistical  analyses  were  performed  using  Stata  software  version  13.1
(StataCorp, College station, TX, United States) and IBM® SPSS® Statistics software
version 25.
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The Nanosight system was used to compare the profiles of particles isolated from the
matched serum and plasma of healthy individuals. The main population of particles
isolated from serum and plasma were similar in size, at 97.7 ± 3.3 nm and 93.1 ± 3.1
nm respectively (Figure 1A).  The range of particle sizes detected in the samples,
including those from the cancer patients (Supplementary Figure 1A), were consistent
with the reported sizes of exosomes (30-150 nm)[16,21,22].  To be consistent with the
Minimal Information for Studies of Extracellular Vesicles 2018 guidelines, we refer
here to the majority particle population in the preparations as “small extracellular
vesicles (sEVs)” , while noting that a minor population of “medium-large extracellular
vesicles (m/lEVs)” were also detected[23]. The average concentration of particles from
healthy controls was 1.2-fold higher in the serum sEV preparations compared to the
matched plasma sEV preparations (Wilcoxon signed-rank test, P = 0.047) (Figure 1B).
However, there was no statistical difference in the yield of particles in the matched
serum sEV preparations  and plasma sEV preparations  from the  cancer  patients
(Wilcoxon signed-rank test, P = 0.56) (Supplementary Figure 1B).
miRNA content in serum and plasma sEV preparations
The number of miRNAs detected was greater in plasma sEV preparations than serum
sEV preparations, either for those detected in each sample (total detectable), or for
those detected in all samples (Figure 2A). In plasma sEV preparations, 480 miRNAs
were detected,  and 45.4% (218 miRNAs)  of  these  were robustly  expressed in  all
samples.  In serum sEV preparations,  412 miRNAs were detected and 31.1% (128
miRNAs) of these were robustly expressed in all samples. Pairwise comparison of the
number of total miRNAs that were detectable was consistently higher in the plasma
sEV preparations (Wilcoxon signed-rank test, P = 0.005) (Figure 2B). The number of
miRNAs unique to plasma sEV preparations was also greater than the number of
miRNAs  unique  to  serum  sEV  preparations  (108  vs  40).  Furthermore,  a  large
proportion of the miRNAs unique to plasma sEV preparations were expressed in at
least 50% of the cohort (at least 5 out of 10 samples) (Supplementary Table 1). While
for miRNAs unique to serum sEV preparations, only 1 miRNA (hsa-miR-1233) was
expressed in at least 50% of the cohort.
The majority of the miRNAs detected in serum sEV preparations were also detected
in plasma sEV preparations. 372 miRNAs were commonly expressed between serum
and plasma sEV preparations, which represented 90.3% of the total miRNA content in
serum sEV preparations.  Of these,  118 miRNAs were commonly expressed in all
serum and plasma sEV preparations. The relative expression of the 372 commonly
expressed miRNAs was significantly correlated (Spearman’s R = 0.87, P  < 0.0001)
(Figure  2C).  There  was  a  stronger  correlation  among the  common 118  miRNAs
expressed in all serum and plasma sEV preparations (Spearman’s R = 0.92, P < 0.0001)
(Figure 2D). Similar observations of the overall miRNA content were found in the
matched serum and plasma sEV preparations from the patients with esophageal
adenocarcinoma (Supplementary Figure 2), although the overall number of miRNAs
were higher in the sEV preparations from the cancer patients compared to healthy
individuals.
Highly expressed miRNAs in serum and plasma sEV preparations
The  top  20  most  abundant  miRNAs  expressed  in  the  serum  and  plasma  sEV
preparations were compared (Table 1). 16 out of 20 of the most abundant miRNAs
were common between serum and plasma sEV preparations. However, the expression
levels  of  the  16  common  miRNAs  were  2  to  11-fold  higher  in  the  plasma  sEV
preparations compared to serum sEV preparations (Wilcoxon signed-rank test, P <
0.05) (Figure 3). Of the 20 most highly expressed miRNAs in plasma sEV preparations,
hsa-miR-484, hsa-miR-130a-3p, hsa-miR-30c-5p and hsa-miR-221-3p were not detected
in serum sEV preparations. Of the 20 miRNAs that were highly expressed in serum
sEV preparations, hsa-miR-1274b, RNU6-1, hsa-miR-517a-3p and hsa-miR-25-3p were
not detected in plasma sEV preparations.
Presence of blood-cell specific miRNAs
The presence of miRNAs reported by Wang et al[10], 2012, and Pritchard et al[8], 2012, to
be highly expressed or uniquely expressed in blood cells was examined in our serum
and  plasma  derived  sEV  preparations.  Both  Wang  et  al[10]  and  Pritchard  et  al[8]
identified hsa-miR-223-3p and hsa-miR-451a as highly abundant in blood cells. Wang
et al[10] reported 27 miRNAs that were uniquely expressed in blood cells. Pritchard et
al[8] 2012 reported 44 additional miRNAs that were highly expressed in blood cells.
Both hsa-miR-223-3p and hsa-miR-451a were found to be among the top 20 most
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Figure 1
Figure 1  NanoSight measurements of isolated vesicles from matched serum and plasma samples. A: The overall size distribution of particles (SEM indicated
by shaded areas) was similar between the matched serum (n = 10) and plasma samples (n = 10); B: Pairwise comparison of the average concentration (± SEM) of
particles demonstrated higher particle yields in serum (Wilcoxon signed-rank test, aP = 0.047).
highly expressed miRNAs in our serum and plasma sEV preparations (Figure 3).
Compared to serum sEV preparations,  hsa-miR-223-3p was expressed at 9.6-fold
higher in plasma sEV preparations (Wilcoxon signed-rank test, P = 0.0051), while hsa-
miR-451a was expressed at 2.5-fold higher in plasma sEV preparations (Wilcoxon
signed-rank test, P = 0.01). An additional 6 blood-cell miRNAs were identified in the
top 20 most highly expressed miRNAs as consistently expressed at higher levels in
plasma sEV preparations compared to serum sEV preparations (2.7 to 5.6 fold; hsa-
miR-19b-3p, hsa-miR-17-5p, hsa-miR-30b-5p, hsa-miR-106a-5p, hsa-miR-150-5p and
hsa-miR-92a-3p; Figure 3). In addition, we identified 4 blood-cell miRNAs (hsa-miR-
98-5p, hsa-miR-30d-3p, hsa-miR-146b-3p and hsa-miR-19b-1-5p) that were robustly
expressed in at least 50% of the plasma sEV preparations, that were not expressed in
the serum sEV preparations (Supplementary Table 1).
Presence of reported vesicular miRNAs and protein-associated miRNAs
The  presence  of  unique  vesicular  miRNAs,  whole  blood  miRNAs  (blood-cell
miRNAs) and cell-free miRNAs (protein-associated miRNAs) reported by Cheng et
al[11] were compared in our plasma and serum sEV preparations (Figure 4). Overall,
we  detected  12  of  Cheng  et  al[11]’s  unique  vesicular  miRNAs  in  our  serum  sEV
preparations, and 14 of Cheng et al[11]’s unique vesicular miRNAs in our plasma sEV
preparations (Figure 4).  Smaller numbers of  Cheng et  al[11]’s  unique whole blood
miRNAs  and  cell-free  miRNAs  were  detected  in  our  plasma  and  serum  sEV
preparations (Figure 4). Several of these unique miRNAs were detected in only a
small number of serum or plasma sEV preparations. We therefore identified those
that were more reliably and robustly expressed in at least 50% of samples. In serum
derived preparations, 6 unique vesicular miRNAs and only 1 unique whole blood
miRNA were robustly expressed. In comparison, there were more unique vesicular
miRNAs (11  miRNAs)  and cell-free  miRNAs (5  miRNAs)  robustly  expressed in
plasma derived preparations. These observations were consistent in the matched
samples from patients with esophageal adenocarcinoma (Supplementary Table 2).
We next evaluated for the presence of vesicle-associated miRNAs and protein-
associated miRNAs reported by Arroyo et al[13] (Figure 5). The list of miRNAs that
were assessable on the TaqMan OpenArray platform are provided in Supplementary
Tables 3 and 4. To investigate the relative expression levels of these miRNAs in serum
and plasma sEV preparations, we partitioned them into the following 5 bins using
their qPCR Ct’s: bin-1, not detected; bin-2, 40 > Ct ≥ 30; bin-3, 30 > Ct ≥ 25; bin-4, 25 >
Ct ≥ 20;  bin-5,  Ct  < 20.  The percentage of  the total  number of  vesicle-associated
miRNAs, and protein-associated miRNAs, was then determined for each bin, for
serum sEV preparations and for plasma sEV preparations.
We  found  that  serum  sEV  preparations  had  a  greater  percentage  of  vesicle-
associated miRNAs expressed at relatively high levels (Ct’s < 25) than plasma sEV
preparations  (60%  vs  44%),  whereas  plasma  sEV  preparations  had  a  greater
percentage of protein-associated miRNAs expressed at relatively high levels than
serum sEV preparations (62% vs 31%; Figure 5). Plasma sEV preparations also had a
greater percentage,  than serum sEV preparations,  of  protein-associated miRNAs
expressed at very high levels (Ct’s < 20; 22% vs 0%), and plasma sEV preparations had
a  higher  percentage  of  undetected  vesicle-associated  miRNAs  than  serum  sEV
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Table 1  Top 20 abundant microRNAs expressed in plasma and serum small extracellular vesicle preparations
Rank Plasma miRNA Relative levels ± SD (× 105) Serum miRNA Relative levels ± SD (× 105)
1 hsa-miR-223-3p1 521.3 ± 310.6 hsa-miR-92a-3p1 100.2 ± 178.0
2 hsa-miR-92a-3p1 268.7 ± 188.5 hsa-miR-223-3p1 53.8 ± 24.8
3 hsa-miR-20a-5p1 89.8 ± 38.3 hsa-miR-451a1 17.6 ± 22.1
4 hsa-miR-19b-3p1 83.2 ± 40.1 hsa-miR-19b-3p1 14.7 ± 15.8
5 hsa-miR-24-3p1 79.0 ± 44.7 hsa-miR-20a-5p1 14.6 ± 14.3
6 hsa-miR-30a-5p1 54.8 ± 31.1 hsa-miR-30a-5p1 9.4 ± 11.0
7 hsa-miR-451a1 43.3 ± 22.0 hsa-miR-320a-3p1 9.3 ± 13.5
8 hsa-miR-320a-3p1 40.1 ± 17.5 hsa-miR-328-3p1 9.1 ± 3.7
9 hsa-miR-484 36.7 ± 23.4 hsa-miR-24-3p1 7.2 ± 3.2
10 hsa-miR-17-5p1 27.2 ± 12.6 hsa-miR-1274b 6.4 ± 3.9
11 hsa-miR-106a-5p1 26.0 ± 11.7 RNU6-1 5.5 ± 4.0
12 hsa-miR-16-5p1 21.2 ± 20.8 hsa-miR-106a-5p1 5.4 ± 4.2
13 hsa-miR-328-3p1 19.2 ± 5.4 hsa-miR-16-5p1 5.1 ± 8.8
14 hsa-miR-130a-3p 17.5 ± 7.2 hsa-miR-17-5p1 5.0 ± 3.9
15 hsa-miR-30c-5p 17.1 ± 11.6 hsa-miR-150-5p1 4.0 ± 2.1
16 hsa-miR-146a-5p1 16.2 ± 12.0 hsa-miR-517a-3p 2.8 ± 2.4
17 hsa-miR-221-3p 13.4 ± 7.2 hsa-miR-30b-5p1 2.1 ± 1.2
18 hsa-miR-150-5p1 13.3 ± 8.5 hsa-miR-146a-5p1 1.8 ± 1.1
19 has-hsa-miR-30b-5p1 11.5 ± 6.6 hsa-miR-191-5p1 1.7 ± 0.9
20 hsa-miR-191-5p1 10.6 ± 5.9 hsa-miR-25-3p 1.6 ± 2.3
1miRNAs were common between serum and plasma.
preparations (33% vs 10%). We observed similar distributions of vesicle-associated
and protein-associated miRNAs in serum and plasma sEV preparations from patients
with esophageal adenocarcinoma (Supplementary Figure 3). Overall these results
indicated that serum sEV preparations contained higher levels of vesicle associated
miRNAs, and lower levels of protein associated miRNAs, compared with plasma sEV
preparations.
Diagnostic performance of multi-biomarker panel in serum and plasma
To investigate whether the above observed differences in proportions of non-vesicular
to vesicular miRNAs in serum and plasma sEV preparations may influence outcomes
of  biomarker  studies,  we compared the  diagnostic  performance  of  a  previously
identified multi-biomarker panel[20] in the matched sEV preparations from serum and
plasma samples (Figure 6). The multi-biomarker panel consisted of 5 specific miRNA
ratios (RNU6-1/hsa-miR-16-5p, hsa-miR-25-3p/hsa-miR-320a, hsa-let-7e-5p/hsa-miR-
15b-5p,  hsa-miR-30a-5p/hsa-miR-324-5p,  hsa-miR-17-5p/hsa-miR-194-5p)  that
discriminated esophageal adenocarcinoma patients from healthy controls and non-
dysplastic Barrett’s esophagus[20]. When assessed in the serum sEV preparations, the
multi-biomarker panel achieved a good prediction accuracy (AUROC = 0.95) and
remained robust in leave-one-out cross validation (AUROC = 0.90). When assessed in
the matched plasma sEV preparations, the multi-biomarker panel was less accurate in
predicting which patients had esophageal  adenocarcinoma (AUROC = 0.80)  and
performed considerably worse in leave-one-out cross validation (AUROC = 0.54).
DISCUSSION
To date,  there have only been limited studies investigating sEV miRNA profiles
concurrently in serum and plasma sEV preparations to determine their suitability for
biomarker studies[11,16]. Based on our overall study findings, we observed significant
differences in the proportion of reported sEV associated miRNAs between serum and
plasma sEV preparations.  Our results  suggest  that  there is  a  greater  concern for
potential contamination of non-vesicular miRNAs in the plasma sEV preparations,
and that this may influence biomarker studies. Therefore, we propose serum to be the
preferred choice over plasma for future sEV miRNA biomarkers studies.
Under our specific study conditions, we isolated similar sEV yields yet overall
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Figure 2
Figure 2  Comparison of the microRNA content between serum and plasma small extracellular vesicles. A: The number of total detectable microRNA (miRNAs)
(top Venn diagram), and the number of miRNAs detected in all serum or plasma samples (bottom Venn diagram), were higher in plasma; B: Pairwise comparison of
the number of total detectable miRNAs was significantly higher in the plasma (Wilcoxon signed-rank test, bP = 0.005); C: Correlation of the average relative
expression of the 372 common total detectable miRNAs (Spearman’s R = 0.87, cP < 0.001); D: Correlation of the average relative expression of the 118 common
miRNAs detected in all serum or plasma samples (Spearman’s R = 0.92, cP < 0.001). miRNA: MicroRNA.
higher  miRNA  content  in  plasma  compared  to  serum  sEV  preparations.  These
findings are in contrast with previous studies that reported an overall higher miRNA
content in serum sEV preparations compared to plasma sEV preparations[11,16].  In
Cheng et al[11],  next generation sequencing was used to profile a larger number of
miRNAs than our TaqMan OpenArray platform. However, the study only utilised
matched samples from 3 healthy individuals and used different methods than us for
sEV isolation. The number of miRNAs detected was also marginally higher in the
serum sEV preparations compared to plasma sEV preparations (412 vs 386 miRNAs).
Although Ding et al[16] used the same sEV isolation and quantification techniques as
us, the blood processing and miRNA detection methods were different to our study.
The  authors  reported  higher  sEV  yield,  higher  albumin  contamination,  larger
microvesicles and higher number of miRNAs detected in the serum compared to
plasma sEV preparations[16]. However, blood samples used for the sEV quantification
and sEV miRNA profiles were derived from different individuals (5 and 20 healthy
individuals respectively). Despite the disparities among these studies, the evidence
that miRNA profiles differ between matched serum and plasma sEV preparations is
consistent.
Possible explanations for the different miRNA profiles of sEV preparations from
serum and plasma might include factors that impact upon the amount of protein-
bound (non-vesicular) miRNAs present, and/or upon the sEVs produced from blood
cells. These factors could include the different tubes with different additives that are
used for producing plasma compared to serum, and that the production of serum
involves blood clotting while the production of plasma specifically avoids this by
using anti-coagulants. Blood clot formation involves trapping an array of proteins into
the clot mesh, and this results in a significantly lower protein content in serum than in
plasma[24],  which may directly contribute towards an overall depletion of protein-
bound miRNAs in serum compared to plasma. Besides Ago2 protein, high density
lipoprotein (HDL) is another type of protein based vehicle for peripherally circulating
miRNAs in plasma[25]. Of particular interest, it has been reported that HDL is trapped
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Figure 3
Figure 3  Fold difference in abundance of the common most abundant microRNAs in plasma compared with
serum small extracellular vesicles preparations. The fold change is calculated as the relative expression in the
plasma divided by the relative expression in the serum. All common abundant microRNAs, including those previously
reported as blood-cell microRNAs by Wang et al[10] and Pritchard et al[8], were significantly higher in the plasma than
serum. (Wilcoxon signed-rank test, bP = 0.0051; dP = 0.007; aP = 0.01).
in the mesh that forms during clotting[26]. Therefore, it is possible that HDL-bound
miRNAs are trapped in the clot, thereby resulting in lower numbers of HDL-bound
miRNAs in serum than plasma. The method that we used for preparing sEVs involves
the precipitation of membrane particles, and methods based upon this technique are
known to result in co-precipitation of lipoproteins[27]. Taken together, it is possible that
our serum sEV preparations contain less HDL-bound miRNAs than our plasma sEV
preparations, and this may explain the lower overall miRNA abundance in our serum
sEV preparations, as well as the tendency for our serum sEV preparations to contain a
higher proportion of sEV associated miRNAs than our plasma sEV preparations.
Different blood collection tube components have been shown to interfere with clinical
chemistry assays in different ways[24].  The blood collection tubes used for plasma
preparation in our study contained EDTA as the anti-coagulant. It has been reported
that EDTA results in platelet activation, which increases the release of microvesicles,
including sEVs, from platelets[28,29]. This might suggest that our plasma preparations
would be more biased, than our serum sEV preparations, towards containing platelet
derived / activated platelet sEV derived miRNAs. Consistent with this possibility, the
top  two  miRNAs  that  were  most  heavily  biased  towards  our  plasma  derived
preparations were hsa-miR-223-3p, which is the most abundant miRNA in platelets,
and hsa-miR-24-3p, which is a biomarker for platelet activation[30]. Another possibility
is that the different blood tube components in the tubes used for preparing serum and
plasma have different impacts upon the number of sEVs produced from blood cells,
and / or the miRNA expression in blood cells, which translates into differences in the
miRNA  composition  of  sEVs  derived  from  them[31].  It  is  also  possible  that  the
differences in blood tube components might impact  upon the specific  blood cell
miRNAs that are sorted into sEVs[31].
One of the most significant differences between the miRNA profiles of our serum
and plasma sEV preparations was the higher level of expression of reported blood cell
miRNAs in plasma sEV preparations. In previous studies, circulating cell-free hsa-
miR-451a, hsa-miR-16-5p and hsa-miR-223-3p are among the most common miRNAs
assessed as indicators of haemolysis or blood cells contamination[10,18,32-35]. Although we
found several reported blood cell miRNAs, including hsa-miR-451a, hsa-miR-16-5p
and hsa-miR-223-3p, to be abundant in both plasma and serum sEV preparations,
they were all more highly expressed in plasma sEV preparations. The presence of
higher blood cell contamination in plasma sEV preparations was further supported by
the observation that several reported blood-cell miRNAs were uniquely expressed
only  in  our  plasma  derived  samples,  and  a  greater  number  of  unique  cell-free
miRNAs, reported by Cheng 2014, were detected in the plasma derived samples.
Although the overall miRNA content was higher in our plasma sEV preparations,
the concern was the high abundance of miRNAs in plasma sEV preparations that
were reported to be from non-vesicular origins. Contrary to the consistently high
miRNA content in plasma compared to serum derived sEV preparations, we observed
a larger percentage of highly expressed vesicle-associated miRNAs in the serum sEV
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Figure 4
Figure 4  Presence of microRNAs reported to be uniquely expressed in whole blood, cell-free, or small extracellular vesicles, in serum and plasma. The lists
of unique miRNAs were derived from Cheng et al[11]. miRNAs detected in at least 50% of each sample type are presented in bold.
preparations, but a larger percentage of highly expressed protein-associated miRNAs
in the matched plasma sEV preparations. We acknowledge that this conclusion is
reliant  on  the  findings  of  a  single  study (Arroyo  2011)  and will  require  further
validation. However, unlike blood-cell miRNAs, specific miRNAs that are highly
expressed or uniquely expressed in sEVs or in protein-complexes with Ago2 are not
as well-established. We identified only two studies, Cheng 2014[11], and Arroyo 2011[13],
comprehensively  reporting specific  sEV miRNA profiles  and protein-associated
miRNA  profiles  in  serum  and  plasma.  Interestingly,  RNU6-1,  which  has  been
reported to be enriched in sEVs, was also found to be abundant in our serum sEV
preparations (top 20 most highly expressed miRNAs) but not in our plasma sEV
preparations[36-39]. Altogether, these findings suggest that although a large proportion
of miRNAs were consistently more highly expressed in plasma sEV preparations
compared to serum sEV preparations, we identified a subset of miRNA candidates
reported to be of sEV origin to be more highly expressed in serum sEV preparations.
Taking all these findings together, serum appears preferable to plasma for sEV
miRNA biomarkers  studies.  As  a  proof-of-concept,  we evaluated the  diagnostic
performance of a multi-biomarker panel to discriminate esophageal adenocarcinoma
patients from the healthy controls in this study cohort when assessed in the serum
sEV preparations compared to plasma sEV preparations. The diagnostic accuracy of
the biomarker panel had higher cross validated prediction accuracy when assessed in
the serum sEV preparations than in plasma sEV preparations. However, we recognise
that our study findings are based on a small sample size and are specific to our study
conditions, and further work is necessary to validate these findings. In particular,
there is currently limited understanding on circulating miRNAs in protein-complexes,
and a need to consider their role in future sEV miRNAs studies.
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Figure 5
Figure 5  Percentage of vesicle-associated (grey) and protein-associated (blue) microRNAs expressed at levels within the indicated cycle threshold range
in small extracellular vesicle preparations from healthy controls. A: Serum; B: Plasma. The list of vesicle-associated and protein-associated miRNAs assessed in
the serum and plasma were derived from Arroyo et al[13]. The bar graphs represent the percentage of microRNAs (miRNAs) within each cycle threshold range out of
the total vesicle-associated miRNAs or protein-associated miRNAs assessed respectively in each sample type. Smoothed lines were added to aid visualisation of the
trends.
Figure 6
Figure 6  Comparison of the diagnostic performance of a previously identified 5-microRNA ratio biomarker panel (Chiam et al[20]) for detecting esophageal
adecarcinoma. A: The diagnostic accuracy of the biomarker panel was assessed by receiver-operating characteristics curve analysis. The area under the curve was
greater in the serum than the plasma; B: The biomarker panel was assessed by leave-one-out-cross validation. The serum small extracellular vesicle preparations
produced greater diagnostic accuracy than the plasma small extracellular vesicle preparations. Healthy individuals, n = 10; esophageal adenocarcinoma, n = 10. AUC:
Area under the curve.
ARTICLE HIGHLIGHTS
Research background
Small extracellular vesicles (sEVs), including exosomes, are shed from tumors into the blood
circulation. These circulating sEVs are an excellent source of microRNA (miRNA) biomarkers for
cancer research. Blood serum and blood plasma both contain sEVs, however at present there is
no consensus on which of these two blood sample types is most useful for biomarker analysis.
Research motivation
Extracellular vesicle preparations derived from serum and plasma are known to be enriched in
sEVs, but they also contain significant amounts of non-vesicle associated miRNAs derived from
sources such as blood cells and protein-bound miRNAs. These non-vesicles associated miRNAs
could interfere with cancer biomarker discovery.  Our study was motivated by the need to
determine which blood sample contains the least amount of non-vesicle associated miRNAs.
This knowledge has the potential to improve cancer biomarker discovery and translation.
Research objectives
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We sought to compare the miRNA profiles between serum and plasma sEV preparations to
determine their suitability for biomarker studies. We also sought to compare the diagnostic
performance of these two sample types using a previously established multi-miRNA biomarker
panel for esophageal adenocarcinoma.
Research methods
Matched serum and plasma samples from 10 healthy controls and 10 patients with esophageal
adenocarcinoma were used for this study. sEVs were isolated with using ExoquickTM.  RNA
extracted from the vesicles was profiled using the Taqman Openarray qPCR.
Research results
The overall miRNA content was higher in plasma sEV preparations (480 miRNAs) and contained
97.5% of the miRNAs found in the serum sEV preparations (412 miRNAs). The expression of
commonly expressed miRNAs was highly correlated (Spearman’s R = 0.87, P <  0.0001) between
the  plasma  and  serum  sEV  preparations  but  was  consistently  higher  in  the  plasma  sEV
preparations. Specific blood-cell miRNAs (hsa-miR-223-3p, hsa-miR-451a, miR-19b-3p, hsa-miR-
17-5p, hsa-miR-30b-5p, hsa-miR-106a-5p, hsa-miR-150-5p and hsa-miR-92a-3p) were expressed
at  2.7  to  9.6  fold  higher  levels  in  the  plasma  sEV  preparations  compared  to  serum  sEV
preparations  (P  <  0.05).  In  plasma sEV preparations,  the  percentage  of  protein-associated
miRNAs expressed at relatively higher levels (cycle threshold 20-25) was greater than serum sEV
preparations (50% vs 31%). While the percentage of vesicle-associated miRNAs expressed at
relatively higher levels was greater in the serum sEV preparations than plasma sEV preparations
(70% vs  44%). A 5-miRNA biomarker panel produced a higher cross validated accuracy for
discriminating patients with esophageal adenocarcinoma from healthy controls using serum sEV
preparations compared with plasma sEV preparations (AUROC 0.80 vs 0.54, P < 0.05).
Research conclusions
Although plasma sEV preparations contained more miRNAs than serum sEV preparations, they
also contained more miRNAs from non-vesicle origins.
Research perspectives
Serum appears to be more suitable than plasma for sEV miRNAs biomarkers studies. Future
studies on sEV associated cancer biomarkers may benefit from using serum as the sample type
for analysis.
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